Menotrophin

Menotrophin provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. The FSH component promotes growth and maturation of ovarian follicles, while the LH component triggers the final maturation and ovulation of the dominant follicle. Together they restore the natural hormonal cascade required for successful ovulation and conception.

The dose of Menotrophin is individualized and set by the prescribing clinician based on the patient’s age, ovarian reserve, response to prior stimulation cycles, and the specific assisted reproductive protocol being used. Dosage adjustments are guided by serial ultrasound monitoring and hormone measurements throughout the treatment cycle.

Menotrophin is not intended for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Limited data are available regarding excretion in breast milk, and because of potential hormonal effects, it is generally advised that breastfeeding mothers avoid Menotrophin unless the benefits outweigh the risks and a specialist approves its use.

To order Menotrophin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Menotrophin contains a combination of FSH and LH activity, whereas some alternatives provide only FSH (e.g., recombinant FSH) or only LH. The dual‑activity profile can be advantageous in patients who require both hormones for optimal follicular development, potentially reducing the need for separate LH supplementation. However, individual response varies, and clinicians choose the preparation that best matches the patient’s hormonal profile and treatment goals.

Menotrophin must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original carton to protect from light, and the vial must not be frozen or shaken. Before use, allow the solution to reach room temperature for a few minutes, and inspect for particulate matter or discoloration; discard if any abnormalities are observed.

Menotrophin is supplied as a sterile solution for subcutaneous injection. The prescriber determines the injection volume and schedule, which is typically administered once daily or as directed by the treatment protocol. Patients are instructed to rotate injection sites, use aseptic technique, and follow any specific guidance provided by their fertility specialist.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain, shortness of breath, and, in rare cases, thromboembolic events. Anaphylactic reactions, though uncommon, are also possible. Early recognition of symptoms and prompt medical evaluation are essential to mitigate these potentially life‑threatening complications.

Menotrophin is contraindicated in individuals with known hypersensitivity to any of its components, uncontrolled thyroid disease, active estrogen‑dependent neoplasms, ovarian cysts larger than 3 cm, or severe pituitary disorders. It should also be avoided in patients with a history of severe OHSS or thromboembolic disease unless a specialist determines that the benefits outweigh the risks.